This Career Development Program (CDP) will be used to prepare new Moffitt investigators at the rank of Assistant Member (Assistant Professor) or equivalent, particularly those already in the field of cutaneous malignancy research, or established Moffitt investigators at the rank of Associate Member (Associate Professor) or higher who are new to the field for careers in translational research of cutaneous malignancies. It will also ease their transition to independence as investigators either in the laboratory or as clinical trialists. The Moffitt Skin SPORE career development program will provide guidance, advice, mentoring, evaluation, and financial resources for continuing support for up to two faculty-level persons per year for 2-3 years each. All prospective projects have a mentor listed that is affiliated with the Skin SPORE or the Comprehensive Melanoma Research Center (CMRC) at Moffitt. The goal is to allow appropriate and motivated individuals to develop an independent research career in translational science focused on cutaneous malignancies. It is not meant as a training program for graduate students, postdoctoral fellows, or clinical fellows in hematology-oncology, surgical oncology or dermatology. In collaboration with the Moffitt Lung SPORE, one CDP award per year may be co-supported by the Skin SPORE, promoting cross-SPORE fertilization. Dr. James Mule will lead the CDP. He has extensive experience in mentoring, research and administration, including serving as a faculty mentor/preceptor on numerous K08, K12, K99/R00 and ACS Fellowship awards, as well as the PI of two T32 training grants. Applications will be reviewed by an Award Evaluation Committee chaired by Dr. Mule using a scientific standard similar to a NIH study section. Scores of 1 (exceptional) to 9 (poor) will be assigned for categories of Significance, Innovation, Scientific quality. Collaboration, and Potential for publication and external funding;with brief justifications and overall impression), using a review form that we had employed previously for use in the CMRC. Progress reports will be required from all funded CDP project applicants at the end of the first six months, and again at the end of the first year of funding. The progress reports will be reviewed by the Award Evaluation Committee consisting of the Moffitt Skin SPORE IAC (see above for a list of members) and ad hoc members. Published manuscripts, abstracts accepted and the potential for translational impact will constitute the most important criteria for renewal of funding for an additional year.

Public Health Relevance

The Pre-SPORE grant at Moffitt expanded by the resources of the CMRC has previously chosen five investigators whose current cutaneous malignancy-related peer reviewed funding totals $1.2 million. Three of those faculty members are now among the funded investigators with proposals submitted as full Projects or to the DRP of the Moffitt Skin SPORE, which speaks to the potential significance and translational impact of the current CDP.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA168536-02
Application #
8754430
Study Section
Special Emphasis Panel (ZCA1-RPRB-M)
Project Start
Project End
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
2
Fiscal Year
2014
Total Cost
$56,654
Indirect Cost
$23,031
Name
H. Lee Moffitt Cancer Center & Research Institute
Department
Type
DUNS #
139301956
City
Tampa
State
FL
Country
United States
Zip Code
33612
Freeman-Keller, Morganna; Kim, Youngchul; Cronin, Heather et al. (2016) Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes. Clin Cancer Res 22:886-94
Pilon-Thomas, Shari; Kodumudi, Krithika N; El-Kenawi, Asmaa E et al. (2016) Neutralization of Tumor Acidity Improves Antitumor Responses to Immunotherapy. Cancer Res 76:1381-90
Smalley, Keiran S M; Fedorenko, Inna V; Kenchappa, Rajappa S et al. (2016) Managing leptomeningeal melanoma metastases in the era of immune and targeted therapy. Int J Cancer 139:1195-201
Prieto-Granada, Carlos N; Wiesner, Thomas; Messina, Jane L et al. (2016) Loss of H3K27me3 Expression Is a Highly Sensitive Marker for Sporadic and Radiation-induced MPNST. Am J Surg Pathol 40:479-89
Emmons, Michael F; Faião-Flores, Fernanda; Smalley, Keiran S M (2016) The role of phenotypic plasticity in the escape of cancer cells from targeted therapy. Biochem Pharmacol 122:1-9
Smalley, Keiran S M; Eroglu, Zeynep; Sondak, Vernon K (2016) Combination Therapies for Melanoma: A New Standard of Care? Am J Clin Dermatol 17:99-105
Sung, Hyeran; Kanchi, Krishna L; Wang, Xue et al. (2016) Inactivation of RASA1 promotes melanoma tumorigenesis via R-Ras activation. Oncotarget 7:23885-96
Fedorenko, I V; Abel, E V; Koomen, J M et al. (2016) Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells. Oncogene 35:1225-35
Nemoto, Satoshi; Mailloux, Adam W; Kroeger, Jodi et al. (2016) OMIP-031: Immunologic checkpoint expression on murine effector and memory T-cell subsets. Cytometry A 89:427-9
Woan, K V; Lienlaf, M; Perez-Villaroel, P et al. (2015) Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: Enhanced antitumor immunity and impaired cell proliferation. Mol Oncol 9:1447-57

Showing the most recent 10 out of 33 publications